Role of NGAL in Vitiligo
Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05290077
Collaborator
(none)
90
1
2
9
10
Study Details
Study Description
Brief Summary
Role of serum Neutrophil Gelatinase-associated Lipocalin in early detection of cardiovascular risk in patients with Vitiligo
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
90 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Role of Serum NGAL Inearly Detection of CVR in Patients With Vitiligo
Anticipated Study Start Date
:
Mar 15, 2022
Anticipated Primary Completion Date
:
May 15, 2022
Anticipated Study Completion Date
:
Dec 15, 2022
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Cases group of vitiligo patients |
Diagnostic Test: NGAL
Serum NGAL in blood for early detection of CVR
|
| Active Comparator: control group healthy group |
Diagnostic Test: NGAL
Serum NGAL in blood for early detection of CVR
|
Outcome Measures
Primary Outcome Measures
- serum Neutrophil Gelatinase-associated Lipocalin in patients with Vitilig [6 months]
Role of serum Neutrophil Gelatinase-associated Lipocalin in early detection of cardiovascular risk in patients with Vitiligo
Eligibility Criteria
Criteria
Ages Eligible for Study:
20 Years
to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
- patients with vitiligo above 20y
Exclusion Criteria:
- patients with systemic disease Pregnants female Lactating females Patients less than 20 y Patients with active lesions
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sohag fuculty | Sohag | Egypt |
Sponsors and Collaborators
- Sohag University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015 Jul 4;386(9988):74-84. doi: 10.1016/S0140-6736(14)60763-7. Epub 2015 Jan 15. Review.
- Mazzei Weiss ME. Vitiligo: to biopsy or not to biopsy? Cutis. 2020 Apr;105(4):189-190.
- Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013 Feb;149(2):159-64.
- Vachiramon V, Onprasert W, Harnchoowong S, Chanprapaph K. Prevalence and Clinical Characteristics of Itch in Vitiligo and Its Clinical Significance. Biomed Res Int. 2017;2017:5617838. doi: 10.1155/2017/5617838. Epub 2017 Jul 30.
Responsible Party:
Doaa Gamal Hafez,
resident doctor at dermatology department sohag university hospital,
Sohag University
ClinicalTrials.gov Identifier:
NCT05290077
Other Study ID Numbers:
- Soh-Med-21-10-20
First Posted:
Mar 22, 2022
Last Update Posted:
Mar 22, 2022
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Doaa Gamal Hafez,
resident doctor at dermatology department sohag university hospital,
Sohag University
Additional relevant MeSH terms: